Showing 391-400 of 3906 results for "".
DermWireTV: Candela + Merz Aesthetics Partnership, COVID-19 Vaccines & Fillers, Almirall's Klisyri, MetSyn & PsO
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-candela-merz-aesthetics-partnership-covid-19-vaccines-and-fillers-almiralls-klisyri-metsyn-and-pso/19893/Klisyri® (tirbanibulin) ointment 1% from Almirall will be available for treatment of AKs by the end of this quarter; Ayman Grada, MD discusses. Are patients who have received dermal filler injections at risk for developing reactions to the COVID-19 vaccine? Joel L. Cohen, MD and Doris Day, MD weighDermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisScientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, ReNovel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical reti2019 Medical Aesthetic Trends
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/2019-medical-aesthetic-trends/19696/What were the hot medical aesthetic trends of 2019 and what’s in the pipeline for 2020? Joel L. Cohen, MD weighs in.Surgical Tips from a Mohs Surgeon
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/surgical-tips-from-a-mohs-surgeon/18694/There are many options for healing defects or treating scars after skin cancer excisions. Joel L. Cohen, MD shares tips for success.UV Talk: Men and Women
https://practicaldermatology.com/topics/skin-cancer-photoprotection/uv-talk-men-and-women/18695/Talk to every patient about UV avoidance, but tailor your patient to each patient's needs and behavior, says Joel L. Cohen, MD. Consider the patient's sex when making recommendations. Watch now to get Dr. Cohen's tip for endurance athletes.To Be Shorr: Negotiate with Confidence
https://practicaldermatology.com/topics/practice-management/to-be-shorr-negotiate-with-confidence/18717/Knowing when and how to negotiate is key. Sometimes, the best outcome is possible when a third party negotiates on your behalf. Jay Shorr explains in this edition of To Be Shorr.Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Driving Growth in the Dermatology Practice
https://practicaldermatology.com/topics/practice-management/driving-growth-in-the-dermatology-practice/18630/Robert Rullo reminds dermatologists to think beyond being just a clinician and to remember they are also running a business. He discusses key business philosophies clinicians need to be aware of and common obstacles that inhibit geometric practice growth. Generations